The Strategic Interval: Outcomes and Implications of the Staged Approach For Early Direct-to-Implant (SAFE-DTI)...

Implant-based breast reconstruction often presents a binary choice: immediate direct-to-implant (DTI) reconstruction or two-stage tissue expander-based reconstruction. Here, we present outcomes of the Staged Approach For Early Direct-to-Implant DTI (SAFE-DTI) protocol in which permanent implants are placed one to three weeks post-mastectomy. Patients undergoing SAFE-DTI were those otherwise eligible for immediate DTI reconstruction in whom (1) there was elevated risk of post-mastectomy flap necrosis, (2) uncertainty regarding their pathologic diagnosis, or (3) logistic challenges between the oncologic and reconstructive surgeon. We reviewed a cohort of 19 patients (32 breasts) who underwent SAFE-DTI at our institution between 2021 and 2025. Most patients underwent nipple-sparing mastectomy (96.9%) followed by SAFE-DTI with a median implant volume of 398cc (IQR 264cc-445cc). The overall complication rate was 18.8%, including infection (6.3%, two breasts in one patient), hematoma (3.1%, one breast) and partial nipple-areolar complex necrosis (9.4%, three breasts, all initially noted prior to implant placement). Four patients (8 breasts, 25% of total) underwent revision within 6 months which consisted primarily of autologous fat grafting for aesthetic optimization. For planned cases, SAFE-DTI leverages the delay phenomenon for improved tissue perfusion, allows confirmation of final pathology, and overcomes logistical scheduling challenges. In salvage cases, it enables the avoidance of tissue expanders when intraoperative tissue perfusion is a concern and immediate DTI is aborted. SAFE-DTI represents a practical technique to mitigate common barriers to immediate DTI reconstruction while preserving its benefits for appropriately selected patients.